FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET (FORESIGHT)

Accurate staging is of great importance in patients with clinically locally advanced primary breast cancer (LABC, stage III) or locoregional recurrent (LRR) breast cancer for making a correct treatment plan. According to current guidelines, staging is performed with positron emission tomography (PET) using the 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) PET tracer, combined with diagnostic computed tomography (CT). However, previous studies have shown that this technique (with the current PET tracer) might not be sufficient for accurate staging. Specifically in low grade, estrogen receptor positive (ER+) breast cancer metastases can be missed due to the low metabolic activity, leading to low uptake of [18F]FDG. Therefore, there is a clinical need to improve staging procedures. 16α-[18F]-fluoro-17β-estradiol ([18F]FES), an ER-targeted PET tracer, allows imaging of ER+ tumor lesions regardless of their metabolic activity. Patients with clinically LABC and LRR have a 25-50% risk of distant metastases. Correct identification of distant metastases allows adaptation of the treatment plan to avoid burdensome treatment with surgery, systemic and radiotherapy in order to maintain quality of life. In case of oligometastases, correct identification increases the likelihood for cure with local treatment. In the current study we will compare disease staging with [18F]FES- and [18F]FDG PET in patients with clinically LABC/LRR breast cancer. Objective: To determine whether [18F]FES PET/CT improves staging for women with clinically LABC or LRR, ER+/HER2- breast cancer as compared to standard [18F]FDG PET/CT. Study design: Multicenter prospective study with invasive measurements. Study population: 20 LABC and 20 LRR ER+/HER2- breast cancer patients. Main study parameters/endpoints: To determine the percentage of patients with a correctly changed treatment plan according to information obtained from [18F]FES PET/CT compared to [18F]FDG PET/CT at staging and at 6 months of follow-up; to determine the percentage of metastatic lesions detected and missed with [18F]FES PET/CT compared to [18F]FDG PET/CT (at staging and during follow-up). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will receive an intravenous cannula for tracer injection and blood sampling, causing potentially transient discomfort at the site of the cannula insertion. Tumor biopsy will be performed from an easy accessible lesion and the most frequent complications that can occur are discomfort, bleeding and (local) infection. The risk of complications from a tumor biopsy is considered low: 0.24-1.6% and 0.11-0.48% for major complications and mortality, respectively. Radiation exposure from a [18F]FES PET and [18F]FDG PET scan usually ranges between 4-11 mSv and 7-8 mSv, respectively. Radiation exposure from a diagnostic CT scan ranges between 8-14 mSv. The total radiation burden is considered justifiable when compared to the information that can be obtained from this study, in this patient group with breast cancer. Imaging with [18F]FES PET may improve staging for patients with breast cancer as it may show tumor lesions that could not be identified with [18F]FDG PET, the current standard for staging. If this is the case, the initial treatment goal and intensity can be adjusted which can have beneficial effects for the patient.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Diagnostic test: 18F-Fluorestradiol PET/CT scan

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Netherlands
  • Noord- Holland
    • Amsterdam, Noord- Holland, Netherlands
      • VU University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Clinically LABC (stage III) or LRR breast cancer (all histological types) with ER+, HER2- and low grade according to Bloom Richardson criteria (grade 1-2)
• Females aged 18 years or older at screening
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
• Candidates for treatment with curative intent (patients are also allowed for inclusion in the current study if they have undergone recent surgery (<6 weeks) for current breast cancer and require staging because of unexpected stage III disease)
• In case [18F]FDG PET/CT has already been performed, patients can be included <21 days after this scan
• Estimated glomerular filtration rate (eGFR) ≥30 ml/min
• Written and signed informed consent

Exclusion Criteria:

• History with another cancer within the last 5 years, except non-melanoma skin cancer
• Undergoing treatment for current breast cancer such as (neo)adjuvant chemotherapy, hormonal therapy (only in case of Tamoxifen), radiotherapy or investigational drug therapy
• Pregnancy or lactating women
• Any medical, psychological or social condition that may interfere with the subject's safety and participation in the study, will lead to exclusion from this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: [18F]FES; All patients will receive an additional PET/CT scan: [18F]FES PET/CT scan.	Diagnostic test: 18F-Fluorestradiol PET/CT scan; [18F]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.; Other Names: [18F]FES PET/CT scan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients with a correctly changed treatment plan according to [18F]FES PET/CT compared to [18F]FDG PET/CT.	Percentage of patients with a correctly changed treatment plan according to information obtained with [18F]FES PET/CT compared to [18F]FDG PET/CT at staging.	2 years
Percentage of metastatic lesions detected with [18F]FES PET/CT compared to [18F]FDG PET/CT.	Percentage of metastatic lesions detected with [18F]FES PET/CT compared to [18F]FDG PET/CT at staging.	2 years
Percentage of missed metastases with [18F]FES PET/CT compared to [18F]FDG PET/CT.	Percentage of missed metastases with [18F]FES PET/CT compared to [18F]FDG PET/CT (at staging and developed during follow-up).	2 years
Percentage of correct treatment plans as well as diagnostic confidence after 6 months of follow-up based on the added information obtained with [18F]FES PET/CT compared to [18F]FDG PET/CT.	Percentage of correct treatment plans as well as diagnostic confidence after 6 months of follow-up as determined by the adjudication committee based on the added information obtained with [18F]FES PET/CT compared to [18F]FDG PET/CT.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
[18F]FES/[18F]FDG uptake related to size of the lesion	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to size of the lesion.	2 years
[18F]FES/[18F]FDG uptake related to location of the lesion.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to location of the lesion.	2 years
[18F]FES/[18F]FDG uptake related to histological subtype.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to histological subtype.	2 years
[18F]FES/[18F]FDG uptake related to grade.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to grade.	2 years
[18F]FES/[18F]FDG uptake related to ER expression level.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to ER expression level.	2 years
[18F]FES/[18F]FDG uptake related to PR expression level.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to PR expression level.	2 years
[18F]FES/[18F]FDG uptake related to HER2 expression level.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to HER2 expression level.	2 years
[18F]FES/[18F]FDG uptake related to Ki67%/mitotic index.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to Ki67%/mitotic index.	2 years
[18F]FES/[18F]FDG uptake related to intensity of ER staining.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to intensity of ER staining.	2 years
[18F]FES/[18F]FDG uptake related to intensity of tumor cell density.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to intensity of tumor cell density.	2 years
[18F]FES/[18F]FDG uptake related to intensity of microvessel density.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to intensity of microvessel density.	2 years
[18F]FES/[18F]FDG uptake related to infiltration of lymphocytes.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to infiltration of lymphocytes.	2 years
[18F]FES/[18F]FDG uptake related to amount of necrosis.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to amount of necrosis.	2 years
[18F]FES/[18F]FDG uptake related to amount of stroma.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to amount of stroma.	2 years
[18F]FES/[18F]FDG uptake related to expression of glucose transporter-1 (GLUT1) in the primary tumor, lymph node and distant metastases.	[18F]FES/[18F]FDG uptake in the primary tumor, lymph node and distant metastases will be related to expression of glucose transporter-1 (GLUT1) in the primary tumor, lymph node and distant metastases.	2 years
Cut off value for [18F]FDG SUV max below which [18F]FES PET/CT adds information for staging.	Cut off value for [18F]FDG SUV max below which [18F]FES PET/CT adds information for staging.	2 years
Cut off value for [18F]FDG SUV peak below which [18F]FES PET/CT adds information for staging.	Cut off value for [18F]FDG SUV peak below which [18F]FES PET/CT adds information for staging.	2 years
Cut off value for grade below which or above which [18F]FES PET/CT adds information for staging.	Cut off value for grade below which or above which, respectively, [18F]FES PET/CT adds information for staging.	2 years
Cut off value for ER expression level below which or above which [18F]FES PET/CT adds information for staging.	Cut off value for ER expression level below which or above which [18F]FES PET/CT adds information for staging.	2 years

Collaborators and Investigators

• Sponsor: Amsterdam UMC, location VUmc

Publications and helpful links

General Publications

• Iqbal R, Menke-van der Houven van Oordt CW, Oprea-Lager DE, Booij J. [18F]FES uptake in the pituitary gland and white matter of the brain. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3009-3010. doi: 10.1007/s00259-021-05281-8. Epub 2021 Mar 17. No abstract available.

Study record dates

Study Major Dates

• Study Start (Actual): November 13, 2018
• Primary Completion (Actual): January 29, 2023
• Study Completion (Actual): January 29, 2023

Study Registration Dates

• First Submitted: October 16, 2018
• First Submitted That Met QC Criteria: October 29, 2018
• First Posted (Actual): November 1, 2018

Study Record Updates

• Last Update Posted (Actual): May 3, 2023
• Last Update Submitted That Met QC Criteria: May 2, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: 2018.451

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No